Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 4, 2010, Pages 511-512

  Sinakos, Emmanouil ^a,b   Dedes, Ioannis ^b   Papalavrentios, Lavrentis ^a,b   Drevelegas, Antonios ^a,b   Akriviadis, Evangelos ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b INTERBALKAN MEDICAL CENTER   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOSIDE ANALOG; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEPATITIS B; HISTOLOGY; HUMAN; LETTER; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77949876548     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521003628335     Document Type: Letter

References (10)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 2008;359(4):378-390
2. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness. Am J Gastroenterol 2008; 103(4):914-921
3. Jiang H, Meng Q, Tan H, Pan S, Sun B, Xu R, et al. Antiangiogenic Therapy Enhances the Efficacy of Transcatheter Arterial Embolization for Hepatocellular Carcinomas. Int J Cancer 2007;121(2):416-424
4. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 Easl Conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421-430
5. Bruix J and Sherman M. Management of Hepatocellular Carcinoma. Hepatology 2005;42(5):1208-1236
6. Reyes D, Azad N, Kamel I, Koteish A, Hamilton J, Pawlik T, et al. Phase II trial of sorafenib combined with doxorubicin eluting bead-transarterial chemoembolization (DEB-TACE) for patients with hepatocellular carcinoma (HCC): interim safety and efficacy analysis. Hepatology 2009;50(6):6A
7. Erhardt A, Kolligs F, Dollinger M, Schott E, Lohse A, Bitzer M, et al. First-in men demonstration of sorafenib plus TACE for the treatment of advanced hepatocellular carcinoma (Socrates trial). Hepatology 2009;50(4)Suppl: 1080A
8. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized Controlled Trial of Transarterial Lipiodol Chemoembolization for Unresectable Hepatocellular Carcinoma. Hepatology 2002;35(5):1164-1171
9. Semela D and Dufour JF. Angiogenesis and Hepatocellular Carcinoma. J Hepatol 2004;41(5):864-880
10. Trotti A, Colevas D, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13(3):176-181